Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice
Posted inClinical Updates Family Medicine & Nutrition Neurology news Specialties

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and nonmotor symptom improvement, but did not change a primary mobility endpoint (TUG) over three weeks.
Posted inClinical Updates Family Medicine & Nutrition Neurology news Pediatrics Specialties

Ketogenic Diet vs Further Antiseizure Medication in Infants with Drug-Resistant Epilepsy: What the KIWE Trial Adds to Clinical Practice

The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.
The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

The Effect of Chitosan Supplementation on Liver Function, Hepatic Steatosis Predictors, and Metabolic Indicators in Adults with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial

This clinical trial evaluates chitosan supplementation's impact on liver health and metabolic markers in adults with NAFLD, showing potential benefits alongside a low-calorie diet.
Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Mediterranean Diet Combined with Early Time-Restricted Feeding: A Promising Strategy for MASLD – Insights from the CHRONO-NAFLD Trial

A 12-week hypocaloric Mediterranean diet with early time-restricted feeding improved glycaemic control and cardiometabolic risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) compared to unrestricted timing or late time-restricted feeding.